The short answer
Fat-free mass is everything in the body that is not fat, skeletal muscle, but also bone, organs, connective tissue, body water and haematopoietic tissue. Reporting a change in fat-free mass as though it were a change in muscle misstates what was measured.
Key facts
- Includes
- Muscle, bone, organs, water, blood-forming tissue
- Muscle share
- Well under half in most adults
- Largest confounder
- Body water shifts
- Bone is affected too
- Stefanakis 2024 (PMID 39481534)
- Common error
- Reading fat-free mass as muscle mass
- Measured by
- DXA, bioimpedance (not directly observed)
What the compartment contains
Body composition analysis divides mass into fat and everything else. That everything else includes skeletal muscle, the skeleton, all internal organs, connective tissue, extracellular and intracellular water, and blood together with the marrow producing it. Skeletal muscle is a substantial component and it is not the majority.
Why water dominates the short-term signal
Body water is a large fraction of fat-free mass and it moves quickly. Glycogen is stored with water, so depleting glycogen reduces measured fat-free mass without any tissue being lost. Early rapid drops in fat-free mass during weight loss are substantially water and glycogen, which is why the early numbers overstate what has happened structurally.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The finding the title of Stefanakis makes explicit
Stefanakis and colleagues published on the impact of weight loss on fat-free mass, muscle, bone and haematopoiesis health in Metabolism in 2024. Listing those four separately is the point: bone and blood-forming tissue are affected by weight loss and are not muscle. A discussion that reduces the whole compartment to muscle has already lost most of what the paper is about.
Why bone matters independently
Bone density responds to mechanical loading, and carrying less mass means less loading. That is a distinct process from muscle protein balance, it operates on a slower timescale, and it has its own long-term consequences. It cannot be addressed by the same interventions that address muscle, which is why it deserves separate consideration rather than being folded into a lean mass discussion.
What this means for reading a percentage
A reported percentage of lean mass lost is a change in a heterogeneous compartment measured by an indirect method. It is not a muscle biopsy. Comparing such percentages between trials that used different methods, at different timepoints, in differently hydrated participants, is considerably less informative than the precision of the numbers implies.
The practical consequence
Compounds designed to preserve muscle address one component of the compartment. Even complete success against muscle loss would leave bone and water changes untouched, so a trial reporting preserved lean mass has not necessarily preserved everything the compartment contains.
Quick reference
| Component | In fat-free mass? | Changes with weight loss |
|---|---|---|
| Skeletal muscle | Yes | Yes (the usual focus) |
| Bone | Yes | Yes (via reduced loading) |
| Body water and glycogen | Yes | Rapidly, early |
| Organs and connective tissue | Yes | Yes |
| Adipose tissue | No | The intended target |
Frequently asked questions
Is fat-free mass the same as muscle mass?
No. It includes bone, organs, connective tissue, body water and blood-forming tissue as well as skeletal muscle.
Why do early fat-free mass drops look so large?
Body water and glycogen move quickly, and glycogen is stored with water. Early changes are substantially fluid rather than tissue.
Does weight loss affect bone?
Yes. Bone responds to mechanical loading, and carrying less mass reduces it, a distinct process from muscle protein balance.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedStefanakis K et al., The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health. Metabolism 2024 (PMID 39481534)pubmed.ncbi.nlm.nih.gov
- PubMedDubin RL et al., GLP-1 agents and weight loss composition. Diabetes Obes Metab 2024 (PMID 39344838)pubmed.ncbi.nlm.nih.gov
- PubMedVermeiren E et al., Comparison of bioimpedance spectroscopy and DXA for assessing body composition changes during weight loss. Eur J Clin Nutr 2021 (PMID 32917962)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Method Determines the NumberDXA and bioimpedance do not agree, and they disagree most during active weight change. Why a lean mass percentage is partly a property of the instrument.
- Blocking the Brake on Muscle GrowthMyostatin restrains muscle growth through activin type II receptors. Blocking them preserves muscle - and a 2024 paper reports it enhances fat loss too.
- Taldefgrobep Alfa: A Second Route Into the Same PathwayA myostatin-directed agent now in a Phase 2 obesity trial. Why more than one compound is targeting the same pathway from different angles.
- The Endpoint Changes When the Patient Is Still GrowingAdult trials report percentage weight loss. Adolescent trials report percent change in BMI - because a growing child gaining height is not failing.
- STEP TEENS and What It Reported201 adolescents, 68 weeks, −16.1% BMI against +0.6% on placebo. The full result including the safety findings that get left out.